Our latest article has been published in Cell Death & Differentiation. The study focuses on the molecular mechanism of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) in highly aggressive breast tumors with Centrosome amplification (CA). We demonstrated, for the first time, that TACC3 forms distinct functional interactomes regulating different processes in mitosis and interphase to ensure proliferation and survival of cancer cells with CA. Read the article here.
Postdoctoral Fellow position to contribute to cancer biology research at the intersection of drug resistance, metastasis, and drug discovery in breast cancer. The Sahin Lab in the Department of Biochemistry and Molecular Biology & Hollings Cancer Center at Medical University of South Carolina (MUSC) in Charleston, South Carolina invites applications for a Postdoctoral Fellow position to contribute to cancer biology research at the intersection of drug resistance, metastasis, and drug discovery in breast cancer. Postdoctoral Read more…
A new postdoctoral fellow position at the intersection of drug resistance, metastasis and drug discovery is available at The Sahin Lab at MUSC Hollings Cancer Center
Link is here: https://www.nature.com/naturecareers/job/postdoctoral-scholar-biochemistry-and-molecular-biology-medical-university-of-south-carolina-musc-761242
Our Lab moved to the Department of Biochemistry & Molecular Biology and Hollings Cancer Center at MUSC!
Dr. Sahin has recently accepted a Professor and SmartState Endowed Chair position at the Dept. of Biochemistry & Molecular Biology and Hollings Cancer Center at Medical University of South Carolina. Starting May 1, our lab is located at HO703 at Hollings Cancer Center.
This 5-year grant will address the mechanisms of resistance to chemotherapy in highly aggressive breast cancers using cutting-edge methodologies, including testing our recently developed LOX inhibitors. NEW positions are available for highly motivated postdocs and graduate students.
This work aims to enhance the efficacy of antibody-drug conjugate (ADC) therapy in aggressive breast cancer. Here is the press release: https://marykayashfoundation.org/what-we-do/cancer-research/grant-recipients/
If you are interested in working at the intersection of mechanisms of drug resistance, metastasis and drug discovery, please apply via: https://www.nature.com/naturecareers/job/postdoctoral-fellow-in-cancer-research-university-of-south-carolina-columbia-sc-746191